YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Natco Pharma

Natco Pharma

BSE: 524816|NSE: NATCOPHARM|ISIN: INE987B01026|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jul 28, 15:16
1014.85
-25.5 (-2.45%)
VOLUME 15,787
LIVE
NSE
Jul 28, 15:20
1014.55
-24.35 (-2.34%)
VOLUME 397,393
News on Natco Pharma
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Buy Natco Pharma; target of Rs 842: Geojit

2.37 pm | 23 Nov 2018 |  Source: Moneycontrol.com

Geojit is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 842 in its research report dated November 21, 2018...

Buy Natco Pharma; target of Rs 930: Anand Rathi

4.53 pm | 16 Nov 2018 |  Source: Moneycontrol.com

Anand Rathi is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 930 in its research report dated November 13,...

Mylan-Natco faces uphill battle in gaining market share from Teva's MS drug

8.05 pm | 09 Nov 2018 |  Source: Moneycontrol.com

Teva’s market share for Copaxone stood at 77-78 percent at the end of the quarter ended September...

Natco Pharma net profit up 115% in Q2FY19

8.06 pm | 05 Nov 2018 |  Source: PTI

During the quarter, the company has witnessed growth in the formulations business, both domestic and exports....

Natco Pharma posts over two-fold jump in Q2 PAT to Rs 181.6 cr

3.38 pm | 05 Nov 2018 |  Source: PTI

The company had posted a consolidated profit after tax of Rs 84.4 crore in the same quarter last fiscal, Natco Pharma said in a regulatory filing....

Natco Q2 PAT seen up 78.6% YoY to Rs. 150 cr: Sharekhan

11.28 am | 17 Oct 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 20 percent Y-o-Y (down 4.9 percent Q-o-Q) to Rs. 512 crore, according to Sharekhan....

Natco's partner Mylan prevails over Teva in Copaxone patent litigation

1.41 pm | 13 Oct 2018 |  Source: Moneycontrol.com

Natco's partner Mylan went ahead and launched Copaxone 40 mg “at-risk” in US in October last year even as the patent litigation is still on. A...

Natco Pharma Q2 PAT seen up 118.2% YoY to Rs. 185 cr: ICICI Direct

5.35 pm | 12 Oct 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 31.3 percent Y-o-Y (up 4 percent Q-o-Q) to Rs. 560.1 crore, according to ICICI Direct....

Buy Natco Pharma, target Rs 905: Shitij Gandhi

11.54 am | 12 Sep 2018 |  Source: Moneycontrol.com

Traders can accumulate the stock in a range of Rs 820-Rs 830 for the upside target of Rs 905 level and a stop loss below Rs 765, says Shitij Gandhi of...

Dr Reddy's eyeing European market for cancer drug

7.52 pm | 13 Aug 2018 |  Source: PTI

In a press release here, Natco said the duxorubicinhydrochloride liposome injection, a therapeutic equivalent to the generic version of Jessens Doxil,...

Dr Reddy's eyeing European market for cancer drug

7.52 pm | 13 Aug 2018 |  Source: PTI

In a press release here, Natco said the duxorubicinhydrochloride liposome injection, a therapeutic equivalent to the generic version of Jessens Doxil,...

Natco Pharma Q1 net profit up 93% to Rs 181 crore

7.56 pm | 08 Aug 2018 |  Source: PTI

Consolidated total revenue of the company stood at Rs 574.5 crore for the quarter under consideration. It was Rs 448.7 crore in the corresponding peri...

How Natco defied the odds to rise up India's pharma ladder

4.47 pm | 06 Jun 2018 |  Source: Moneycontrol.com

Copaxone is expected to deliver another windfall in FY19 for Natco, before tapering-off slowly in FY20 with the launches from other generic rivals....

Natco Pharma Q4 PAT seen up 78.5% YoY to Rs. 315.3 cr: Edelweiss

6.25 pm | 16 Apr 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 29 percent Y-o-Y (up 30.5 percent Q-o-Q) to Rs. 745.1 crore, according to Edelweiss....

Buy Natco Pharma; target of Rs 908: Geojit

5.08 pm | 09 Apr 2018 |  Source: Moneycontrol.com

Geojit is bullish on Natco Pharma has recommended buy rating on the stock with a target price of Rs 908 in its research report dated April 09, 2018....

Natco launches generic version of multiple sclerosis drug in India

8.03 pm | 04 Apr 2018 |  Source: PTI

The company has launched the product under brand name 'Denopsy', Natco Pharma said in a filing to BSE....

Natco Pharma seeks USFDA approval for hepatitis drug

1.59 pm | 01 Mar 2018 |  Source: PTI

Drug firm Natco Pharma today said it has filed an abbreviated new drug application (ANDA) for Sofosbuvir Tablets, 400mg, with the United States Food a...

Natco Pharma Q3 net profit up 12% at Rs 217.4 cr 

3.20 pm | 06 Feb 2018 |  Source: PTI

The company had posted a profit after tax of Rs 194.9 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing....

1 2
Quick Links for Natco Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.